Haleon H2 Earnings Call Highlights

Core Viewpoint - Haleon anticipates a challenging cold and flu season in Q1 2026, with expectations for organic sales growth of 3%–5% in 2026, driven by improved competitiveness and category growth initiatives [1][2][4]. Financial Performance - Haleon reported 2025 organic sales growth of 3%, below the medium-term target of 4%–6%, primarily due to a milder cold and flu season and weak consumer confidence [6][7]. - The company achieved a gross margin improvement of 220 basis points and generated £1.9 billion in free cash flow, supported by an ongoing £800 million productivity program [5][18]. - A £500 million buyback allocation and a 7.6% increase in the full-year dividend to 7.1p were announced [4]. Market Outlook - The U.S. market is expected to return to growth in 2026, with inventory levels now deemed appropriate [2]. - Haleon is focusing on driving category growth through increased investment in advertising and promotion, innovation, and a new operating model [2][8]. Strategic Initiatives - A new chief growth officer role has been created to enhance marketing capabilities and commercial execution, with a shift from three regions to six operating units [8][9]. - The company is implementing AI-driven tools for net revenue management and pricing actions, aiming for a flatter organizational structure [9][10]. Brand and Category Performance - Oral health products, particularly Sensodyne and parodontax, are performing well, with significant growth in emerging markets like India and China [13][14]. - Haleon is addressing opportunities in digestive health and pain relief, with brands like TUMS and Voltaren showing strong market positions [16][17]. Investment and Growth Focus - Haleon increased advertising and promotion spending by 7.5% and R&D by 7.7% in 2025, emphasizing sustainable growth investments [19]. - The company is focused on maintaining a strong working/non-working media split, with 60% of working media allocated to digital channels [19].